



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory A. Demopoulos et al.

Attorney Docket No. OMER117356
(PH.1.0017.US2)

Application No.: 09/839,633

Group Art Unit: 1646

Filed: April 20, 2001

Examiner: Eileen B. O'Hara

Title: METHOD OF INHIBITION OF PAIN AND INFLAMMATION DURING SURGERY
COMPRISING ADMINISTRATION OF SOLUBLE TNF RECEPTORS (AS
AMENDED)

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING
REJECTION OVER PRIOR PATENTS AND A PROVISIONAL REJECTION OVER
A COPENDING PATENT APPLICATION

TO THE COMMISSIONER FOR PATENTS:

Your petitioner, Omeros Corporation, having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, represents that it is owner of the entire right, title and interest in the above application by an assignment from the inventor(s) of the patent application identified above. The assignment to Omeros Medical Systems, Inc. was recorded in the U.S. Patent and Trademark Office at Reel 012076, Frame 0551 and a subsequent change of name to Omeros Corporation was recorded at Reel 012916, Frame 0530.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of the undersigned's knowledge and belief, title is in the assignee identified above.

Your petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the

01/19/2005 SDIRETA1 00000039 09839633

01 FC:2814

65.00 OP

expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior U.S. Patent Nos. 5,820,583, 6,056,715, 6,210,394, 6,413,961, 6,254,585, 6,420,432, 6,492,332, 6,645,168 and which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer filed prior to the grant, of any patent issuing from co-pending Application No. 10/180,815 filed June 25, 2002, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to prior U.S. Patent Nos. 5,820,583, 6,056,715, 6,210,394, 6,413,961, 6,254,585, 6,420,432, 6,492,332, 6,645,168 and any patent issuing from co-pending Application No. 10/180,815, this agreement to run with any patent granted on said above-identified application and to be binding upon the grantee, its successors, or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of prior U.S. Patent Nos. 5,820,583, 6,056,715, 6,210,394, 6,413,961, 6,254,585, 6,420,432, 6,492,332, 6,645,168 or the expiration date of the full statutory term, as presently shortened by any terminal disclaimer filed prior to the grant of any patent issuing from co-pending Application No. 10/180,815 in the event that said prior U.S. Patent Nos. 5,820,583, 6,056,715, 6,210,394, 6,413,961, 6,254,585, 6,420,432, 6,492,332, 6,645,168 and any patent issuing from co-pending Application No. 10/180,815 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned (whose title is supplied below) is empowered to act on behalf of the organization.


The terminal disclaimer fee of \$65 under 37 C.F.R. § 1.20 is included.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

OMEROS CORPORATION

1/11/05

Date



Name: Marcia S. Kelbon
USPTO Reg. No. 34,358
Title: Vice President, Patent & General Counsel

MSK:sj